Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 60Breast Neoplasms 22Thyroid Neoplasms 20Neoplasms 20Multiple Endocrine Neoplasia Type 1 20Carcinoma, Renal Cell 20Melanoma 19Carcinoma, Non-Small-Cell Lung 19Adrenocortical Carcinoma 19Small Cell Lung Carcinoma 17Thyroid Cancer, Papillary 16Colorectal Neoplasms 16Thyroid Carcinoma, Anaplastic 15Carcinoma, Neuroendocrine 15Carcinoma, Medullary 14Prostatic Neoplasms 13Pheochromocytoma 13Pancreatic Neoplasms 13Lung Neoplasms 13Carcinoma, Hepatocellular 13Carcinoid Tumor 13Insulinoma 12Uterine Cervical Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Neoplasm Metastasis 11Head and Neck Neoplasms 11Adenocarcinoma, Follicular 11Salivary Gland Neoplasms 10Pituitary Neoplasms 10Colonic Neoplasms 10

Interventions

relacorilant 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Pathologic Processes × Endocrine × Clear all
NCT04373265 2024-02-23

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Corcept Therapeutics

Phase 1 Completed
15 enrolled
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Adrenal Gland Diseases, Adrenocortical Hyperfunction, Cushing Syndrome, Diabetes Mellitus, Type 2, Endocrine System Diseases, Hyperglycemia, Hypertension, Pathologic Processes, Glucose Intolerance, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡